  Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through
its binding to both NTS1 and NTS2 receptors and NT analogs provide stronger
pain relief than morphine on a molecular basis. Here, we examined the
analgesic/adverse effect profile of a new NT(8-13) derivative denoted JMV2009,
in which the Pro10 residue was substituted by a silicon-containing unnatural
amino acid silaproline. We first report the synthesis and in vitro
characterization (receptor-binding affinity, functional activity and stability)
of JMV2009. We next examined its analgesic activity in a battery of acute,
tonic and chronic pain models. We finally evaluated its ability to induce
adverse effects associated with chronic opioid use, such as constipation and
analgesic tolerance or related to NTS1 activation, like hypothermia. In in
vitro assays, JMV2009 exhibited high binding affinity for both NTS1 and NTS2,
improved proteolytic resistance as well as agonistic activities similar to NT,
inducing sustained activation of p42/p44 MAPK and receptor internalization.
Intrathecal injection of JMV2009 produced dose-dependent antinociceptive
responses in the tail-flick test and almost completely abolished the
nociceptive-related behaviors induced by chemical somatic and visceral noxious
stimuli. Likewise, increasing doses of JMV2009 significantly reduced tactile
allodynia and weight bearing deficits in nerve-injured rats. Importantly,
chronic agonist treatment did not result in the development of analgesic
tolerance. Furthermore, JMV2009 did not cause constipation and was ineffective
in inducing hypothermia. These findings suggest that NT drugs can act as an
effective opioid-free medication for the management of pain or can serve as
adjuvant analgesics to reduce the opioid adverse effects.
